Treatments for opioid addiction are categorized as either substitution therapies—the opioid receptor agonists methadone, buprenorphine, and buprenorphine / naloxone combinations—or abstinence therapies—the opioid receptor antagonist naltrexone. Physicians and patients prefer opioid receptor agonists. Indivior’s Suboxone Film has been one of the most widely prescribed opioid receptor agonists in the United States, and with direct generic competition beginning in early 2019, buprenorphine / naloxone sublingual film products will likely remain a treatment mainstay. In general, these treatments are associated with the potential for misuse and diversion, and relapse rates among patients are high. This report explores the current prescribing practices for opioid addiction in the United States, the factors influencing treatment decisions, and the changes in prescribing that are expected to occur in the coming year.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 102 psychiatrists in the United States.
Key companies: Alkermes, BioDelivery Sciences, Braeburn, Indivior, Orexo
Key drugs: Bunavail, methadone, Probuphine, Sublocade, Suboxone Film, Subutex, Vivitrol, Zubsolv
Key insights provided: